Global Allogeneic T Cell Therapies Market Report and Forecast 2024-2032

Global Allogeneic T Cell Therapies Market Report and Forecast 2024-2032


Global Allogeneic T-Cell Therapies Market Outlook

The growth of the global allogeneic T cell therapies market size is being driven by the increasing interest of pharmaceutical companies across the globe. The market size is anticipated to grow at a CAGR of 9.8% during the forecast period of 2024-2032.

Allogeneic T Cell Therapies: Introduction

Allogeneic T cell therapies are a type of immunotherapy that harnesses the power of T cells from healthy donors to treat various diseases, particularly cancer. T cells, a type of white blood cells, play a central role in the immune system's response to foreign substances, such as cancer cells or pathogens. Allogeneic T cell therapies involve isolating T cells from healthy donors, modifying them to enhance their anti-cancer activity, and then infusing them into patients to target and destroy cancer cells.

Allogeneic T cell therapies have shown promising results in the treatment of various haematological malignancies, including leukaemia, lymphoma, and multiple myeloma. They are also being investigated for solid tumours and other diseases, such as viral infections and autoimmune disorders. Ongoing research aims to optimize their efficacy, safety, and applicability to a broader range of diseases.

Key Trends in the Global Allogeneic T Cell TherapiesMarket

Key trends in the allogeneic T cell therapies market:
  • Advancements in Genetic Engineering: The field of genetic engineering is rapidly evolving, and there are ongoing efforts to enhance the anti-cancer properties of allogeneic T-cell therapies. Researchers are exploring novel gene-editing techniques, such as CRISPR/Cas9, to precisely modify T cells and improve their efficacy and safety profiles.
  • Expansion into Solid Tumours: While allogeneic T cell therapies have shown remarkable success in hematological malignancies, there is a growing focus on expanding their applications to solid tumors. Researchers are working on identifying suitable target antigens and developing strategies to overcome the challenges associated with the tumor microenvironment.
  • Combination Therapies: Combining allogeneic T-cell therapies with other treatment modalities, such as immune checkpoint inhibitors, targeted therapies, or radiation, is gaining attention. Combination therapies have the potential to enhance the effectiveness of allogeneic T-cell therapies by promoting a synergistic anti-cancer immune response. Clinical trials evaluating the safety and efficacy of combination approaches are ongoing, and positive results could lead to the development of more effective treatment regimens.
  • Scalable Manufacturing Processes: With the increasing demand for allogeneic T-cell therapies, there is a need for scalable and cost-effective manufacturing processes. Researchers and companies are focusing on developing efficient manufacturing strategies that can produce large quantities of consistent and high-quality allogeneic T-cell products.
  • Expansion of Clinical Trials: The number of clinical trials investigating allogeneic T-cell therapies is rapidly expanding. These trials aim to evaluate the safety, efficacy, and long-term outcomes of these therapies in different cancer types and patient populations. Additionally, clinical trials are exploring the use of allogeneic T-cell therapies in combination with other treatments or as a follow-up therapy after stem cell transplantation.
Global Allogeneic T Cell TherapiesMarket Segmentations

The market can be categorized into product type, therapeutics indications, end user, and region.

Market Breakup by Product Type
  • Chimeric Antigen Receptor (CAR) T Cell Therapies
  • T Cell Receptor (TCR) Therapies
  • Others
Market Breakup by Therapeutics Indications
  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Others
Market Breakup by End User
  • Hospitals
  • Speciality Clinics
  • Research Institutes
  • Others
Market Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Global Allogeneic T Cell Therapies Market Overview

The market for allogeneic T-cell therapies is experiencing substantial growth. The increasing prevalence of cancer and the demand for more effective treatment options are driving the market expansion. The market is expected to witness significant investments in research and development, manufacturing infrastructure, and commercialization activities. The allogeneic T cell therapies market is becoming increasingly competitive, with several biotechnology and pharmaceutical companies actively participating in research and development. Companies are striving to establish a competitive edge through innovative technologies, partnerships, and therapeutic advancements.

As allogeneic T cell therapies approach commercialization, access and affordability are significant considerations. The high costs of these therapies raise concerns about equitable access for patients. Payers and healthcare systems are grappling with reimbursement models that ensure patient access to these novel and potentially life-saving treatments. In summary, the allogeneic T cell therapies market is witnessing rapid growth and remarkable progress in the treatment of various cancers. Ongoing research, technological advancements, and regulatory developments will play pivotal roles.

Key Players in the Global Allogeneic T Cell Therapies Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the allogeneic T cell therapies market are as follows:
  • Athersys Inc.
  • Mesoblast Ltd.
  • Biorestorative Therapies Inc.
  • Pluristem Inc.
  • Brainstorm Cell Limited.
  • ViaCyte Inc.
  • Gamida Cell
  • HOPE BIOSCIENCES
  • Cellular Biomedicine Group
  • Smith+Nephew
  • MEDIPOST
  • ANTEROGEN.CO, LTD.
  • NuVasive Inc.
  • RTI Surgical
  • AlloSource
  • JCR Pharmaceuticals Co. Ltd.
  • Takeda Pharmaceutical Company Limited
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Allogeneic T Cell Therapies Market Overview
3.1 Global Allogeneic T Cell Therapies Market Historical Value (2017-2023)
3.2 Global Allogeneic T Cell Therapies Market Forecast Value (2024-2032)
4 Global Allogeneic T Cell Therapies Market Landscape
4.1 Global Allogeneic T Cell Therapies Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Allogeneic T Cell Therapies Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Indications
4.2.3 Analysis by End User
5 Global Allogeneic T Cell Therapies Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Allogeneic T Cell Therapies Market Segmentation
6.1 Global Allogeneic T Cell Therapies Market by Product Type
6.1.1 Market Overview
6.1.2 Chimeric Antigen Receptor (CAR) T Cell Therapies
6.1.3 T Cell Receptor (TCR) Therapies
6.1.4 Others
6.2 Global Allogeneic T Cell Therapies Market by Therapeutics Indications
6.2.1 Market Overview
6.2.2 Cancer
6.2.3 Autoimmune Diseases
6.2.4 Infectious Diseases
6.2.5 Others
6.3 Global Allogeneic T Cell Therapies Market by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Specialty Clinics
6.3.4 Research Institutes
6.3.5 Others
6.4 Global Allogeneic T Cell Therapies Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Allogeneic T Cell Therapies Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Allogeneic T Cell Therapies Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Allogeneic T Cell Therapies Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Allogeneic T Cell Therapies Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Allogeneic T Cell Therapies Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Athersys Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 Mesoblast Ltd.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 Biorestorative Therapies Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 Pluristem Inc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Brainstorm Cell Limited.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 ViaCyte Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 Gamida Cell
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 HOPE BIOSCIENCES
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 Cellular Biomedicine Group
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 Smith+Nephew
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisition
17.10.5 Certifications
17.11 MEDIPOST
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 ANTEROGEN.CO, LTD.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
17.13 NuVasive Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisition
17.13.5 Certifications
17.14 RTI Surgical
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisition
17.14.5 Certifications
17.15 AlloSource
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisition
17.15.5 Certifications
17.16 JCR Pharmaceuticals Co. Ltd.
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisition
17.16.5 Certifications
17.17 Takeda Pharmaceutical Company Limited
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisition
17.17.5 Certifications
18 Global Allogeneic T Cell Therapies Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings